Physicians know that serum creatinine levels can prove difficult to interpret at the onset of declining renal function and can be influenced by nonrenal factors. To ensure the best patient outcomes, there is an opportunity to find better ways of monitoring renal allograft health.
A noninvasive assay like AlloSure® could have a significant impact in aiding in the diagnosis of rejection.
Dr. Robert Montgomery, Transplant Surgeon at NYU Langone Health and Dr. Chris Larsen, Transplant Surgeon at Emory University discuss the future of xenotransplantation including Dr. Montgomery’s work, the recent cardiac xenotransplant at the University of Maryland, the regulatory pathways for xenotransplant, and the role of current and experimental immunosuppressive drugs in making xenotransplant a reality.
When caring for a complex—and increasing—patient population, limited budgets combined with high turnover rates have always been top concerns for transplant center administrators.
